tetano
Editor, Senior Moderator
Nat Med
. 2020 Sep 3.
doi: 10.1038/s41591-020-1070-6. Online ahead of print.
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Lisa H Tostanoski[SUP] 1 [/SUP], Frank Wegmann[SUP] 2 [/SUP], Amanda J Martinot[SUP] 1 3 [/SUP], Carolin Loos[SUP] 4 5 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Noe B Mercado[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Chi N Chan[SUP] 6 [/SUP], Stephen Bondoc[SUP] 6 [/SUP], Carly E Starke[SUP] 6 [/SUP], Michael Nekorchuk[SUP] 6 [/SUP], Kathleen Busman-Sahay[SUP] 6 [/SUP], Cesar Piedra-Mora[SUP] 1 3 [/SUP], Linda M Wrijil[SUP] 3 [/SUP], Sarah Ducat[SUP] 3 [/SUP], Jerome Custers[SUP] 2 [/SUP], Caroline Atyeo[SUP] 4 7 [/SUP], Stephanie Fischinger[SUP] 4 7 [/SUP], John S Burke[SUP] 4 [/SUP], Jared Feldman[SUP] 4 7 [/SUP], Blake M Hauser[SUP] 4 7 [/SUP], Timothy M Caradonna[SUP] 4 7 [/SUP], Esther A Bondzie[SUP] 1 [/SUP], Gabriel Dagotto[SUP] 1 7 [/SUP], Makda S Gebre[SUP] 1 7 [/SUP], Catherine Jacob-Dolan[SUP] 1 7 [/SUP], Zijin Lin[SUP] 1 [/SUP], Shant H Mahrokhian[SUP] 1 [/SUP], Felix Nampanya[SUP] 1 [/SUP], Ramya Nityanandam[SUP] 1 [/SUP], Laurent Pessaint[SUP] 8 [/SUP], Maciel Porto[SUP] 8 [/SUP], Vaneesha Ali[SUP] 8 [/SUP], Dalia Benetiene[SUP] 8 [/SUP], Komlan Tevi[SUP] 8 [/SUP], Hanne Andersen[SUP] 8 [/SUP], Mark G Lewis[SUP] 8 [/SUP], Aaron G Schmidt[SUP] 4 7 9 [/SUP], Douglas A Lauffenburger[SUP] 5 [/SUP], Galit Alter[SUP] 4 9 [/SUP], Jacob D Estes[SUP] 6 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Roland Zahn[SUP] 2 [/SUP], Dan H Barouch[SUP] 10 11 12 13 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death[SUP]1-4[/SUP]. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters[SUP]5-7[/SUP] and nonhuman primates[SUP]8-10[/SUP] have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates[SUP]11-13[/SUP]. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
. 2020 Sep 3.
doi: 10.1038/s41591-020-1070-6. Online ahead of print.
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Lisa H Tostanoski[SUP] 1 [/SUP], Frank Wegmann[SUP] 2 [/SUP], Amanda J Martinot[SUP] 1 3 [/SUP], Carolin Loos[SUP] 4 5 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Noe B Mercado[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Chi N Chan[SUP] 6 [/SUP], Stephen Bondoc[SUP] 6 [/SUP], Carly E Starke[SUP] 6 [/SUP], Michael Nekorchuk[SUP] 6 [/SUP], Kathleen Busman-Sahay[SUP] 6 [/SUP], Cesar Piedra-Mora[SUP] 1 3 [/SUP], Linda M Wrijil[SUP] 3 [/SUP], Sarah Ducat[SUP] 3 [/SUP], Jerome Custers[SUP] 2 [/SUP], Caroline Atyeo[SUP] 4 7 [/SUP], Stephanie Fischinger[SUP] 4 7 [/SUP], John S Burke[SUP] 4 [/SUP], Jared Feldman[SUP] 4 7 [/SUP], Blake M Hauser[SUP] 4 7 [/SUP], Timothy M Caradonna[SUP] 4 7 [/SUP], Esther A Bondzie[SUP] 1 [/SUP], Gabriel Dagotto[SUP] 1 7 [/SUP], Makda S Gebre[SUP] 1 7 [/SUP], Catherine Jacob-Dolan[SUP] 1 7 [/SUP], Zijin Lin[SUP] 1 [/SUP], Shant H Mahrokhian[SUP] 1 [/SUP], Felix Nampanya[SUP] 1 [/SUP], Ramya Nityanandam[SUP] 1 [/SUP], Laurent Pessaint[SUP] 8 [/SUP], Maciel Porto[SUP] 8 [/SUP], Vaneesha Ali[SUP] 8 [/SUP], Dalia Benetiene[SUP] 8 [/SUP], Komlan Tevi[SUP] 8 [/SUP], Hanne Andersen[SUP] 8 [/SUP], Mark G Lewis[SUP] 8 [/SUP], Aaron G Schmidt[SUP] 4 7 9 [/SUP], Douglas A Lauffenburger[SUP] 5 [/SUP], Galit Alter[SUP] 4 9 [/SUP], Jacob D Estes[SUP] 6 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Roland Zahn[SUP] 2 [/SUP], Dan H Barouch[SUP] 10 11 12 13 [/SUP]
Affiliations
- PMID: 32884153
- DOI: 10.1038/s41591-020-1070-6
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death[SUP]1-4[/SUP]. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters[SUP]5-7[/SUP] and nonhuman primates[SUP]8-10[/SUP] have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates[SUP]11-13[/SUP]. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.